Full Text Journal Articles by
Author Elizabeth Garrett Mayer

Advertisement

Find full text journal articles






Sunitinib in Patients with Metastatic Colorectal Cancer (mCRC) with FLT-3 Amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

Tareq Al Baghdadi, Elizabeth Garrett-Mayer, Susan Halabi, Pam K Mangat, Patricia Rich, Eugene R Ahn, Seungjean Chai, Andrew L Rygiel, Olufunlayo Osayameh, Kaitlyn R Antonelli, Samiha Islam, Suanna S Bruinooge, Richard L Schilsky,

BACKGROUND:TAPUR is a pragmatic, phase II basket study evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancers harboring genomic alterations known to be drug targets. Sunitinib is an oral multikinase inhibitor of FMS-like tyrosine kinase-3 (FLT-3), among other targets. Results from a cohort of patients ... Read more >>

Target Oncol (Targeted oncology)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Development and implementation of the SUM breast cancer cell line functional genomics knowledge base.

Stephen P Ethier, Stephen T Guest, Elizabeth Garrett-Mayer, Kent Armeson, Robert C Wilson, Kathryn Duchinski, Daniel Couch, Joe W Gray, Christiana Kappler,

Several years ago, the SUM panel of human breast cancer cell lines was developed, and these cell lines have been distributed to hundreds of labs worldwide. Our lab and others have developed extensive omics data sets from these cells. More recently, we performed genome-scale shRNA essentiality screens on the entire ... Read more >>

NPJ Breast Cancer (NPJ breast cancer)
[2020, 6:30]

Cited: 0 times

View full text PDF listing >>



Advertisement

An assessment of racial differences in epidemiological, clinical and psychosocial factors among head and neck cancer patients at the time of surgery.

Anvesh Kompelli, Kathleen B Cartmell, Katherine R Sterba, Anthony J Alberg, Christopher C Xiao, Amit J Sood, Elizabeth Garrett-Mayer, Shai J White-Gilbertson, Steven A Rosenzweig, Terry A Day,

Objective:Racial disparities have been well characterized and African American (AA) patients have 30% lower 5-year survival rates than European Americans (EAs) for head and neck squamous carcinoma (HNSCC). This poorer survival can be attributed to a myriad of different factors. The purpose of this study was to characterize AA-EA similarities ... Read more >>

(World journal of otorhinolaryngology - head and neck surgery)
[2020, 6(1):41-48]

Cited: 0 times

View full text PDF listing >>



Development and Validation of a Prognostic Model for Patients with Advanced Lung Cancer Treated with the Immune Checkpoint Inhibitor Atezolizumab.

Ashley M Hopkins, Ganessan Kichenadasse, Elizabeth Garrett-Mayer, Christos S Karapetis, Andrew Rowland, Michael J Sorich,

PURPOSE:Immune checkpoint inhibitors (ICI) are a significant advance to the treatment of advanced non-small cell lung cancer (NSCLC); however, their initiation is associated with heterogeneity in outcomes. This study aimed to develop and validate a prognostic tool of survival in patients with advanced NSCLC treated with ICIs. EXPERIMENTAL DESIGN:A pretreatment ... Read more >>

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2020, 26(13):3280-3286]

Cited: 0 times

View full text PDF listing >>



Nicotine replacement therapy sampling for smoking cessation within primary care: results from a pragmatic cluster randomized clinical trial.

Matthew J Carpenter, Amy E Wahlquist, Jennifer Dahne, Kevin M Gray, Elizabeth Garrett-Mayer, K Michael Cummings, Robert Davis, Brent M Egan,

BACKGROUND AND AIMS:Within the context of busy clinical settings, health-care providers need practical, evidence-based options to engage smokers in quitting. Sampling of nicotine replacement therapy [i.e. provision of nicotine replacement therapy (NRT starter kits)] is a brief, pragmatic strategy to address this need. We aimed to compare the effects of ... Read more >>

Addiction (Addiction (Abingdon, England))
[2020, 115(7):1358-1367]

Cited: 0 times

View full text PDF listing >>



Geographically distributed data should be analyzed with spatial epidemiologic methods.

Elizabeth Garrett-Mayer,

Cancer (Cancer)
[2020, 126(6):1161-1162]

Cited: 0 times

View full text PDF listing >>



Discrepancies in Financial Self-Disclosures and Open Payments Reporting Among Authors of Clinical Oncology Research Studies.

Elizabeth Garrett-Mayer, Melinda W Kaltenbaugh, Rebecca Spence, Suanna S Bruinooge, Clifford A Hudis, Dina Michels, Richard L Schilsky,

PURPOSE:Company-reported payments from the Open Payments database (OP) have been compared with self-disclosed financial relationships made by physician authors. Discrepancies have been viewed as under-reporting of financial relationships. Our goal was to perform a systematic comparison to determine sources of discordance between company-reported and self-reported financial relationships. METHODS:Financial disclosures reported ... Read more >>

J. Clin. Oncol. (Journal of clinical oncology : official journal of the American Society of Clinical Oncology)
[2020, 38(5):480-487]

Cited: 0 times

View full text PDF listing >>



Delivery of TRAIL-expressing plasmid DNA to cancer cells in vitro and in vivo using aminoglycoside-derived polymers.

Sheba Goklany, Ping Lu, Sudhakar Godeshala, Andrea Hall, Elizabeth Garrett-Mayer, Christina Voelkel-Johnson, Kaushal Rege,

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a death ligand that can preferentially induce apoptosis in cancer cells over normal cells. The transmembrane form of TRAIL has been shown to elicit much stronger activity than its soluble counterpart but delivery is a potential challenge. Here, we investigated the potential of ... Read more >>

J Mater Chem B (Journal of materials chemistry. B)
[2019, 7(44):7014-7025]

Cited: 0 times

View full text PDF listing >>



Assessing an ASCO Decision Aid for Improving the Accuracy and Attribution of Serious Adverse Event Reporting From Investigators to Sponsors.

Kathryn F Mileham, Caroline Schenkel, Meredith K Chuk, Andrea Buchmeier, Raymond P Perez, Patricia Hurley, Laura A Levit, Elizabeth Garrett-Mayer, Courtney Davis, Suanna S Bruinooge, Julie Vose,

PURPOSE:Investigators often send reports to sponsors that incorrectly categorize adverse event (AE)s as serious or attribute AEs to investigational drugs. Such errors can contribute to high volumes of uninformative investigational new drug safety reports that sponsors submit to the US Food and Drug Administration and participating investigators, which strain resources ... Read more >>

J Oncol Pract (Journal of oncology practice)
[2019, 15(12):e1050-e1065]

Cited: 0 times

View full text PDF listing >>



Attributable Failure of First-line Cancer Treatment and Incremental Costs Associated With Smoking by Patients With Cancer.

Graham W Warren, Kathleen B Cartmell, Elizabeth Garrett-Mayer, Ramzi G Salloum, K Michael Cummings,

Importance:Previous studies have shown that continued smoking among patients with cancer can increase overall and cancer-specific mortality, risk for second primary cancer, and risk for toxic effects of cancer treatment. To our knowledge, there have been no efforts to estimate additional costs for cancer treatment attributed to smoking. Objective:To model ... Read more >>

JAMA Netw Open (JAMA network open)
[2019, 2(4):e191703]

Cited: 6 times

View full text PDF listing >>



Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in Oncology.

Brian P Hobbs, Pedro C Barata, Yada Kanjanapan, Channing J Paller, Jane Perlmutter, Gregory R Pond, Tatiana M Prowell, Eric H Rubin, Lesley K Seymour, Nolan A Wages, Timothy A Yap, David Feltquate, Elizabeth Garrett-Mayer, William Grossman, David S Hong, S Percy Ivy, Lillian L Siu, Steven A Reeves, Gary L Rosner,

Traditionally, drug development has evaluated dose, safety, activity, and comparative benefit in a sequence of phases using trial designs and endpoints specifically devised for each phase. Innovations in drug development seek to consolidate the phases and rapidly expand accrual with "seamless" trial designs. Although consolidation and rapid accrual may yield ... Read more >>

J Natl Cancer Inst (Journal of the National Cancer Institute)
[2019, 111(2):118-128]

Cited: 2 times

View full text PDF listing >>



Deletion of the murine ortholog of the 8q24 gene desert has anti-cancer effects in transgenic mammary cancer models.

Collin Homer-Bouthiette, Yang Zhao, Lauren B Shunkwiler, Benjamine Van Peel, Elizabeth Garrett-Mayer, Rachael C Baird, Anna I Rissman, Stephen T Guest, Stephen P Ethier, Manorama C John, Patricia A Powers, Jill D Haag, Michael N Gould, Bart M G Smits,

BACKGROUND:The gene desert on human chromosomal band 8q24 harbors multiple genetic variants associated with common cancers, including breast cancer. The locus, including the gene desert and its flanking genes, MYC, PVT1 and FAM84B, is also frequently amplified in human breast cancer. We generated a megadeletion (MD) mouse model lacking 430-Kb ... Read more >>

BMC Cancer (BMC cancer)
[2018, 18(1):1233]

Cited: 1 time

View full text PDF listing >>



Comparative Assessment of Clinical Benefit Using the ESMO-Magnitude of Clinical Benefit Scale Version 1.1 and the ASCO Value Framework Net Health Benefit Score.

Nathan I Cherny, Elisabeth G E de Vries, Urania Dafni, Elizabeth Garrett-Mayer, Shannon E McKernin, Martine Piccart, Nicola J Latino, Jean-Yves Douillard, Lowell E Schnipper, Mark R Somerfield, Jan Bogaerts, Dimitris Karlis, Panagiota Zygoura, Katerina Vervita, George Pentheroudakis, Josep Tabernero, Christoph Zielinski, Dana S Wollins, Richard L Schilsky,

PURPOSE:To better understand the European Society for Medical Oncology-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) and the ASCO Value Framework Net Health Benefit score version 2 (ASCO-NHB v2), ESMO and ASCO collaborated to evaluate the concordance between the frameworks when used to assess clinical benefit attributable to new ... Read more >>

J. Clin. Oncol. (Journal of clinical oncology : official journal of the American Society of Clinical Oncology)
[2019, 37(4):336-349]

Cited: 11 times

View full text PDF listing >>



Understanding the role of advanced practice providers in oncology in the United States.

Suanna S Bruinooge, Todd A Pickard, Wendy Vogel, Amy Hanley, Caroline Schenkel, Elizabeth Garrett-Mayer, Eric Tetzlaff, Margaret Rosenzweig, Heather Hylton, Shannon N Westin, Noël Smith, Conor Lynch, Michael P Kosty, Stephanie F Williams,

PURPOSE:Advanced practice providers (APPs, which include NPs and physician assistants [PAs]) are integral members of oncology teams. This study aims first to identify all APPs in oncology and, second, to understand personal and practice characteristics (including compensation) of those APPs. METHODS:We identified APPs who practice oncology from membership and claims ... Read more >>

JAAPA (JAAPA : official journal of the American Academy of Physician Assistants)
[2018, 31(12):1-12]

Cited: 0 times

View full text PDF listing >>



Understanding the Role of Advanced Practice Providers in Oncology in the United States.

Suanna Bruinooge, Todd A Pickard, Wendy Vogel, Amy Hanley, Caroline Schenkel, Elizabeth Garrett-Mayer, Eric Tetzlaff, Margaret Rosenzweig, Heather Hylton, Shannon N Westin, Noel Smith, Conor Lynch, Michael P Kosty, Stephanie F Williams,

PURPOSE:Advanced practice providers (APPs, which include nurse practitioners [NPs] and physician assistants [PAs]) are integral members of oncology teams. This study aims to identify all oncology APPs and to understand personal and practice characteristics (including compensation) of those APPs. METHODS:We identified APPs who practice oncology from membership and claims data. ... Read more >>

Oncol Nurs Forum (Oncology nursing forum)
[2018, 45(6):786-800]

Cited: 0 times

View full text PDF listing >>



Advanced glycation end products are elevated in estrogen receptor-positive breast cancer patients, alter response to therapy, and can be targeted by lifestyle intervention.

Katherine R Walter, Marvella E Ford, Mathew J Gregoski, Rita M Kramer, Kendrea D Knight, Laura Spruill, Lourdes M Nogueira, Bradley A Krisanits, Van Phan, Amanda C La Rue, Michael B Lilly, Stefan Ambs, King Chan, Tonya F Turner, Heidi Varner, Shweta Singh, Jaime Uribarri, Elizabeth Garrett-Mayer, Kent E Armeson, Ebony J Hilton, Mark J Clair, Marian H Taylor, Andrea M Abbott, Victoria J Findlay, Lindsay L Peterson, Gayenell Magwood, David P Turner,

PURPOSE:Lifestyle factors associated with personal behavior can alter tumor-associated biological pathways and thereby increase cancer risk, growth, and disease recurrence. Advanced glycation end products (AGEs) are reactive metabolites produced endogenously as a by-product of normal metabolism. A Western lifestyle also promotes AGE accumulation in the body which is associated with ... Read more >>

Breast Cancer Res. Treat. (Breast cancer research and treatment)
[2019, 173(3):559-571]

Cited: 2 times

View full text PDF listing >>



Understanding the Role of Advanced Practice Providers in Oncology in the United States.

Suanna S Bruinooge, Todd A Pickard, Wendy Vogel, Amy Hanley, Caroline Schenkel, Elizabeth Garrett-Mayer, Eric Tetzlaff, Margaret Rosenzweig, Heather Hylton, Shannon N Westin, Noël Smith, Conor Lynch, Michael P Kosty, Stephanie F Williams,

Purpose: Advanced practice providers (APPs, which include nurse practitioners [NPs] and physician assistants [PAs]) are integral members of oncology teams. This study aims first to identify all oncology APPs and, second, to understand personal and practice characteristics (including compensation) of those APPs. Methods: We identified APPs who practice oncology from ... Read more >>

(Journal of the advanced practitioner in oncology)
[2018, 9(6):585-598]

Cited: 1 time

View full text PDF listing >>



The effect of bone marrow graft composition on pediatric bone marrow transplantation outcomes.

Vanessa Fabrizio, Amy Wahlquist, Elise Hill, Elizabeth Williams, Cindy Kramer, Jennifer Jaroscak, Angie Duong, Elizabeth Garrett-Mayer, Michelle Hudspeth,

Hematopoietic stem cell graft cellular composition has been generally accepted to impact outcomes. Recent studies question this hypothesis. We conducted a single-center retrospective study of sixty-one pediatric BMT recipients for malignant (68%) and nonmalignant diseases (32%) examining effects of graft composition on engraftment, acute GVHD, chronic GVHD, and survival at ... Read more >>

Pediatr Transplant (Pediatric transplantation)
[2018, 22(8):e13287]

Cited: 0 times

View full text PDF listing >>



State Tobacco Policies as Predictors of Evidence-Based Cessation Method Usage: Results From a Large, Nationally Representative Dataset.

Jennifer Dahne, Amy E Wahlquist, Elizabeth Garrett-Mayer, Bryan W Heckman, K Michael Cummings, Matthew J Carpenter,

Introduction:Evidence-based cessation methods including nicotine replacement therapy (NRT), non-NRT medications, quitlines, and behavioral treatments are underutilized by smokers attempting to quit. Although a number of studies have demonstrated a relationship between state-level tobacco policies (eg, taxation, appropriations) and cessation, whether such state-level factors influence likelihood of using an evidence-based treatment ... Read more >>

Nicotine Tob. Res. (Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco)
[2018, 20(11):1336-1343]

Cited: 1 time

View full text PDF listing >>



Understanding the Role of Advanced Practice Providers in Oncology in the United States.

Suanna S Bruinooge, Todd A Pickard, Wendy Vogel, Amy Hanley, Caroline Schenkel, Elizabeth Garrett-Mayer, Eric Tetzlaff, Margaret Rosenzweig, Heather Hylton, Shannon N Westin, Noël Smith, Conor Lynch, Michael P Kosty, Stephanie F Williams,

PURPOSE:Advanced practice providers (APPs, which include nurse practitioners [NPs] and physician assistants [PAs]) are integral members of oncology teams. This study aims first to identify all oncology APPs and, second, to understand personal and practice characteristics (including compensation) of those APPs. METHODS:We identified APPs who practice oncology from membership and ... Read more >>

J Oncol Pract (Journal of oncology practice)
[2018, 14(9):e518-e532]

Cited: 1 time

View full text PDF listing >>



Nicotine replacement therapy sampling via primary care: Methods from a pragmatic cluster randomized clinical trial.

Jennifer Dahne, Amy E Wahlquist, Amy S Boatright, Elizabeth Garrett-Mayer, Douglas O Fleming, Robert Davis, Brent Egan, Matthew J Carpenter,

BACKGROUND:Primary care is the most important point of healthcare contact for smokers. Brief physician advice to quit, based on the 5As/AAR model, offers some efficacy but is inconsistently administered and has limited population impact. Nicotine replacement therapy (NRT) sampling, defined as provision of a brief NRT starter kit, when added ... Read more >>

Contemp Clin Trials (Contemporary clinical trials)
[2018, 72:1-7]

Cited: 1 time

View full text PDF listing >>



Rationale and Design of the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

Pam K Mangat, Susan Halabi, Suanna S Bruinooge, Elizabeth Garrett-Mayer, Ajjai Alva, Katherine A Janeway, Philip J Stella, Emile Voest, Kathleen J Yost, Jane Perlmutter, Navin Pinto, Edward S Kim, Richard L Schilsky,

Purpose:Case reports and small prospective trials suggest that administering targeted therapies to patients with advanced cancer and an identified genomic target may be associated with clinical benefit. The TAPUR Study, a phase II, prospective, non-randomized, multi-basket, pragmatic clinical trial aims to identify signals of drug activity when Food and Drug ... Read more >>

(JCO precision oncology)
[2018, 2018:]

Cited: 8 times

View full text PDF listing >>



The State of Oncology Practice in America, 2018: Results of the ASCO Practice Census Survey.

M Kelsey Kirkwood, Amy Hanley, Suanna S Bruinooge, Elizabeth Garrett-Mayer, Laura A Levit, Caroline Schenkel, Jerome E Seid, Blase N Polite, Richard L Schilsky,

PURPOSE:To describe the US hematology and medical oncology practice landscape and to report findings of the sixth annual ASCO Oncology Practice Census survey. PARTICIPANTS AND METHODS:ASCO used Medicare Physician Compare data to characterize oncology practices in the United States. Practice size, number of care sites, and geographic distribution were determined. ... Read more >>

J Oncol Pract (Journal of oncology practice)
[2018, 14(7):e412-e420]

Cited: 14 times

View full text PDF listing >>



Multicenter Phase IB Trial of Carboxyamidotriazole Orotate and Temozolomide for Recurrent and Newly Diagnosed Glioblastoma and Other Anaplastic Gliomas.

Antonio Omuro, Kathryn Beal, Katharine McNeill, Robert J Young, Alissa Thomas, Xuling Lin, Robert Terziev, Thomas J Kaley, Lisa M DeAngelis, Mariza Daras, Igor T Gavrilovic, Ingo Mellinghoff, Eli L Diamond, Andrew McKeown, Malbora Manne, Andrew Caterfino, Krishna Patel, Linda Bavisotto, Greg Gorman, Michael Lamson, Philip Gutin, Viviane Tabar, Debyani Chakravarty, Timothy A Chan, Cameron W Brennan, Elizabeth Garrett-Mayer, Rashida A Karmali, Elena Pentsova,

Purpose Carboxyamidotriazole orotate (CTO) is a novel oral inhibitor of non-voltage-dependent calcium channels with modulatory effects in multiple cell-signaling pathways and synergistic effects with temozolomide (TMZ) in glioblastoma (GBM) models. We conducted a phase IB study combining CTO with two standard TMZ schedules in GBM. Methods In cohort 1, patients ... Read more >>

J. Clin. Oncol. (Journal of clinical oncology : official journal of the American Society of Clinical Oncology)
[2018, 36(17):1702-1709]

Cited: 9 times

View full text PDF listing >>



Preoperative predictors of occult nodal disease in cT1N0 oral cavity squamous cell carcinoma: Review of 2623 cases.

Kevin Y Zhan, Patrick F Morgan, David M Neskey, Joanne J Kim, Andrew T Huang, Elizabeth Garrett-Mayer, Terry A Day,

BACKGROUND:Nodal disease predicts survival in oral cavity squamous cell carcinoma (SCC). Currently, no large studies on predictors of occult nodal disease in cT1N0 oral cavity SCC exist. METHODS:The National Cancer Database (NCDB) review for cT1N0 oral cavity SCC with surgical resection and elective neck dissection (END). RESULTS:The number of patients ... Read more >>

Head Neck (Head & neck)
[2018, 40(9):1967-1976]

Cited: 2 times

View full text PDF listing >>



Advertisement

Disclaimer
1.1863 s